Click Diagnostics

About this entry

Click Diagnostics was founded with the mission to dramatically improve health outcomes by providing physicians with “patient-side” test results that enable immediate and accurate treatment.

Through dramatic miniaturization and cost reduction of canonical PCR technology, Click has created a rapid, easy-to-use, inexpensive, disposable diagnostic device. The device requires minimal training: simply input sample, activate device, wait 20 minutes, and visually read colorimetric results. The device will revolutionize health care by moving molecular testing from laboratories and large healthcare facilities to doctors’ offices and clinics, and eventually the home. Click’s first product simultaneously detects chlamydia, gonococcus, and trichomonas. The US NIH is funding a clinical trial of the device, expected to be complete in late 2018 with commercial availability in 2019. In a project proposed here, Click will partner with British STI experts to integrate a new assay onto the existing STI platform to detect drug resistant Neisseria gonorrhoeae (drNG). Use of this device will enable clinicians to detect NG in a clinical sample and identify an effective treatment, in the same clinic visit. drNG is as an urgent threat; nearly 30% of NG infections are antibiotic resistant with the potential of becoming virtually untreatable. Treating patients with the narrowest, but still effective, antibiotic for their infection requires clinicians to ascertain drug susceptibility in real time to inform prescription decisions. Real-time testing for drug resistance would dramatically improve patient management by providing individualized treatment, thus reducing the prescription of unnecessary antibiotics and slowing the development of resistance to extended-spectrum cephalosporins.

If you would like to be introduced to this team for collaboration, get in touch with the Longitude prize.
Pathogen(s)
Sexually transmitted infections